Biocon Biologics Completes Integration of Viatris Biosimilars, Becomes World's Largest
Biocon's scale in biosimilars positions India as the global hub for affordable biologics, potentially transforming access to cancer and autoimmune treatments across developing Asia.
Biocon Biologics completed integrating Viatris's biosimilars business, creating the world's largest pure-play biosimilars company with 20+ molecules and commercial presence in 120+ countries.
Biocon Biologics has completed the integration of Viatris's biosimilars business, creating the world's largest pure-play biosimilars company with a portfolio of 20+ molecules and commercial presence in 120+ countries. The combined entity reported annualized revenue of $2.1 billion and aims to make biologics accessible to patients across emerging markets in Asia, Africa, and Latin America.
Biocon's scale in biosimilars positions India as the global hub for affordable biologics, potentially transforming access to cancer and autoimmune treatments across developing Asia.
Where this signal fits in the broader landscape.
No recent signals tracked yet.
https://www.biocon.com/newsroom
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In